Gene expression analysis of tumor-antigen PRAME in hepatocellular carcinoma and its possible involvement in tumor progression
| Project/Area Number |
26830076
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | Okayama University of Science (2015)
Tottori University (2014) |
|---|
Principal Investigator |
Kanki Keita 岡山理科大学, 工学部, 准教授 (10516876)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 肝細胞癌 / レチノイン酸シグナル / 悪性化 / PRAME / レチノイン酸 |
|---|
| Outline of Final Research Achievements |
PRAME (Preferentially expressed antigen in melanoma) is known to be involved in malignancy of various tissues. We performed a gene expression analysis with 100 HCC samples, finding that high PRAME expression in tumor tissue was associated with malignant characteristics such as clinical stage IV, high tumor markar levels, and early recurrence after surgical resection. In non-tumor tissue, PRAME-positive patients showed early recurrence and poor prognosis. Western blot analysis revealed that undifferentiated HCC cells, such as HLE and HLF, showed high level of PRAME expression compared to differentiated HCC cells, PLC/PRF5, HepG2, HuH1, HuH7. Thus, PRAME expression may be a useful marker for a progression and early recurrence of HCC.
We also investigated the molecular mechanism that retinoic acid signaling sensitizes HCC cells to apoptosis induced by sorafenib.
|
Report
(3 results)
Research Products
(16 results)
